CliffBio
biologic

ITVISMA

onasemnogene abeparvovec-brve

Loss of exclusivityNovember 2037projected — 12-year biologic exclusivity estimate
CompanyNovartis Gene Therapies, Inc.

Drug detail

Brand nameITVISMA
Active ingredientonasemnogene abeparvovec-brve
Strength4x10^13VG/ML
Dosage formInjection
RouteIntrathecal
ModalityBiologic
FDA approvalNovember 2025
Marketing statusRx

More from Novartis Gene Therapies, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

ITVISMA patent cliff — loss of exclusivity November 2037 | CliffBio